

any interested person may petition FDA, on or before June 5, 1996, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must contain sufficient facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Dockets Management Branch (address above) in three copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. Comments and petitions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: November 30, 1995.
 Stuart L. Nightingale,
Associate Commissioner for Health Affairs.
 [FR Doc. 95-29808 Filed 12-6-95; 8:45 am]
BILLING CODE 4160-01-F

Health Resources and Services Administration

Agency Forms Undergoing Paperwork Reduction Act Review

Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget, in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for review, call the HRSA Reports Clearance Office on (301)-443-1129.

The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995: Health Education Assistance Loan (HEAL) Program Physician's Certification of Borrower's Total and Permanent Disability Form—New—This form, completed by the HEAL borrower, the borrower's physician, and the holder of the loan, is used to certify that the

HEAL borrower meets the total and permanent disability provisions. The PHS will use this form to obtain precise information about the disability claim which includes the following: (1) The borrower's consent to release medical records to the Department of Health and Human Services and to the holder of the borrower's HEAL loans, (2) pertinent information supplied by the certifying physician, (3) the physician's certification that the borrower is unable to engage in any substantial gainful activity because of a medically determinable impairment that is expected to continue for a long and indefinite period of time or to result in death, and (4) information from the lender on the unpaid balance. Failure to submit the required documentation will result in a disability claim not being honored.

Type of respondent	Number of respondents	Responses per respondent	Average burden per response	Total burden (hours)
Borrower	42	1.0	0.08	3
Physician	42	1.0	2.75	116
Lender	35	1.2	0.17	7

Estimated Total Annual Burden: 126 hours.

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Allison Eydt, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: December 1, 1995.
 J. Henry Montes,
Associate Administrator for Policy Coordination
 [FR Doc. 95-29810 Filed 12-6-95; 8:45 am]
BILLING CODE 4160-15-P

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 36 U.S.C. 207 or pursuant to 42 U.S.C.

241 to achieve expeditious commercialization of results of federally-funded research and development.

ADDRESSES: Licensing information for the technologies referenced below may be obtained by contacting Stephen Finley, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804 (telephone 301/496-7056 ext 215; fax 301/402-0220).

cDNA Sequence of a Clone Encoding Arylalkylamine N-acetyltransferase

Klein et al. (NICHD)

[DHHS Reference No. E-161-95/0]

and

Human Gene Encoding Serotonin N-acetyltransferase

Klein et al. (NICHD)

[DHHS Reference No. E-222-95/0]

The identification of an arylalkylamine N-acetyltransferase (AA-NAT) mRNA in the brain and the cloning of ovine and human cDNAs encoding for the pineal enzyme

serotonin N-acetyltransferase. These findings open a new area of research—the importance of AA-NAT in the regulation of brain serotonin and the development of drugs which raise serotonin levels by inhibiting this enzyme. This enzyme is the rate-controlling step in the conversion of serotonin to melatonin. The hormone melatonin has been linked to controlling circadian rhythms. Development of regulators of the synthesis of the hormone melatonin may be the preferred route to controlling seasonal reproduction cycles or sleep cycles of vertebrates. Activators of the serotonin N-acetyltransferase may be beneficial to induce or enhance the quality of sleep at night. Inhibitors of serotonin N-acetyltransferase may lead to drugs that stimulate the levels of alertness and physical activity or delay the onset of fatigue. Licenses for the cDNAs encoding for this enzyme or the production of the enzyme are available.

Dated: November 20, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 95-29761 Filed 12-6-95; 8:45 am]

BILLING CODE 4140-01-M

National Institute on Aging; Notice of Meeting of the National Advisory Council on Aging

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the National Advisory Council on Aging, National Institutes on Aging, Thursday, February 1, and Friday, February 2, 1996, to be held at the National Institutes of Health, Building 31, Conference Room 6, Bethesda, Maryland. This meeting will be open to the public on Thursday, February 1, from 8:00 a.m. to 3:00 p.m. for a status report by the Director, NIA; a review of NIA Programs; a report on the Working Group on Program; a report on the Minority Task Force Meeting; and a discussion of program policies and issues, recent legislation, and other items of interest.

The meeting will be open again on Friday, February 2, from 8:00 a.m. until adjournment for a report on the Advisory Committee to the Director, NIH; a report by the Director, National Institute of Neurological Disorders and Stroke; and a review of NIA Programs. Attendance by the public will be limited to space available.

In accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Public Law 92-463, the meeting of the Council will be closed to the public on Thursday, February 1, from 3:00 p.m. to adjournment for the review, discussion and evaluation of grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Ms. June McCann, Committee Management Officer for the National Institute on Aging, National Institutes of Health, Gateway Building, 7201 Wisconsin Avenue, Suite 2C218, Bethesda, Maryland 20892 (301/496-9322), will provide a summary of the meeting and a roster of committee members upon request.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should

contact Ms. McCann at (301) 496-9322, in advance of the meeting.

(Catalog of Federal Domestic Assistance Program No. 93.866, Aging Research, National Institutes of Health)

Dated: December 1, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-29757 Filed 12-6-95; 8:45 am]

BILLING CODE 4140-01-M

National Institute of General Medical Sciences; Meeting of the National Advisory General Medical Sciences Council

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the National Advisory General Medical Sciences Council, National Institute of General Medical Sciences, National Institutes of Health, on January 25-26, 1996, Building 45, Rooms E1 and E2, Bethesda, Maryland.

This meeting will be open to the public from 11 a.m. to 6 p.m. on January 25, and from 8:30 a.m. to 10:30 a.m. on January 26, for the discussion of program policies and issues, opening remarks, report of the Acting Director, NIGMS, and other business of Council. Attendance by the public will be limited to space available.

In accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), title 5, U.S.C. and sec. 10(d) of Pub. L. 92-463, the meeting will be closed to the public on January 25 from 8:30 a.m. to 11 a.m., and on January 26, from 10:30 a.m. until adjournment, for the review, discussion, and evaluation of individual grant applications. The discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Mrs. Ann Dieffenbach, Public Information Officer, National Institute of General Medical Services, National Institutes of Health, Natcher Building, Rooms 3AS-43H, Bethesda, Maryland 20892, telephone: 301-496-7301, FAX 301-402-0224, will provide a summary of the meeting, and a roster of Council members. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mrs. Dieffenbach in advance of the meeting. Dr. W. Sue Shafer, Executive Secretary, NAGMS Council, National Institutes of Health, Natcher Building, Rooms 2AN-32C, Bethesda, Maryland 20892, telephone: 301-594-

4499 will provide substantive program information upon request.

(Catalog of Federal Domestic Assistance Program Nos. 93.821, Biophysics and Physiological Sciences; 93.859, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS]; Special Programs, 93.960)

Dated: December 1, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-29758 Filed 12-6-95; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Allergy and Infectious Diseases; Notice of Meetings: National Advisory Allergy and Infectious Diseases Council; Acquired Immunodeficiency Syndrome Subcommittee; Allergy and Immunology Subcommittee; Microbiology and Infectious Diseases Subcommittee

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the National Advisory Allergy and Infectious Diseases Council, National Institute of Allergy and Infectious Diseases, and its subcommittees on January 29-31, 1996. Meetings of the Council, NAAIDC Allergy and Immunology Subcommittee and the NAAIDC Microbiology and Infectious Diseases Subcommittee will be held at the National Institutes of Health, Building 31C. The meeting of the NAAIDC Acquired Immunodeficiency Syndrome Subcommittee will be held at the National Institutes of Health, Natcher Building, Bethesda, Maryland.

The meeting of the full Council will be open to the public on January 29 in Conference Room 6 from approximately 1 p.m. until 3:30 p.m. for opening remarks of the Institute Director, discussion of procedural matters, Council business, and a report from the Institute Director which will include a discussion of budgetary matters. The primary program will include an update on reinvention activities, a presentation on emerging microbes and a report on recommendations of the NIAID, Program Announcement Working Group.

On January 30 the meetings of the NAAIDC Allergy and Immunology Subcommittee and NAAIDC Microbiology and Infectious Diseases Subcommittee will be open to the public from 8:30 a.m. until adjournment. The subcommittees will meet in conference rooms 8 and 6 respectively. The meeting of the